
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna is projected to experience significant revenue growth, with product sales expected to rise from $1.73 billion in 2025 to $2.15 billion in 2026, supported by a robust pipeline of 35 mRNA development candidates addressing various therapeutic areas. The company has also demonstrated improvements in manufacturing efficiency, which are anticipated to expand gross margins from 30% in 2023 back to 50% by 2025, enhancing overall financial performance. Additionally, a recently secured $1.5 billion debt deal is expected to bolster Moderna's balance sheet, providing flexibility to navigate uncertainties and capitalize on future growth opportunities.
Bears say
The financial analysis reveals a negative outlook on Moderna's stock due to several factors impacting revenue growth potential. The projected decline in COVID vaccine sales from $18 billion in 2022 to $6.7 billion in 2023, along with anticipated long-term revenue reductions related to COVID vaccines, highlight significant headwinds for the company. Additionally, challenges from competitive products in the respiratory vaccine space and slow progress in their development pipeline contribute to concerns over overall future profitability and revenue stability.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares